Academic Journal
Προβολή σε EDS

A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment in IgA nephropathy

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment in IgA nephropathy
Συγγραφείς: Canney, M, Shan, S, Er, L, Billot, L, Han, J, Wong, MG, Monaghan, H, Hladunewich, M, Hooi, LS, Jha, V, Lv, J, Perkovic, V, Zhang, H, Cattran, DC, Barbour, SJ, Jha, Vivekanand
Πηγή: urn:ISSN:0085-2538 ; urn:ISSN:1523-1755 ; Kidney International, 109, 4, 738-749
Στοιχεία εκδότη: Elsevier
Έτος έκδοσης: 2026
Συλλογή: UNSW Sydney (The University of New South Wales): UNSWorks
Θεματικοί όροι: 32 Biomedical and Clinical Sciences, 3202 Clinical Sciences, Clinical Trials and Supportive Activities, Kidney Disease, Clinical Research, Precision Medicine, 6.1 Pharmaceuticals, Adult, Female, Humans, Male, Middle Aged, Adrenal Cortex Hormones, Glomerular Filtration Rate, Glomerulonephritis, IGA, Glucocorticoids, Methylprednisolone, Proportional Hazards Models, Time Factors, Treatment Outcome, Secondary Data Analysis, IgA nephropathy, clinical trial, corticosteroids, kidney failure, prediction, response, TESTING trial steering committee, anzsrc-for: 32 Biomedical and Clinical Sciences
Περιγραφή: Introduction: Corticosteroids are effective for treating IgA nephropathy but have important adverse effects. In this secondary analysis of the TESTING cohort, we generated a model to predict, for an individual patient, the probability that they will respond to corticosteroids. Methods: Time to the primary outcome (40% reduction in eGFR, kidney failure or death due to kidney disease) was evaluated in a Cox proportional hazards model including all potential treatment modifiers as main effects. Selected variables were forced into a model with treatment exposure and interaction terms between treatment and each included variable. The predicted four-year absolute risk of the primary outcome was generated for every patient individually under separate scenarios of being treated with methylprednisolone or placebo. The difference between the two scenarios was the predicted individual treatment effect on absolute risk reduction (ARR). Model performance was assessed using discrimination plots, restricted mean survival time (RMST) and the C-statistic for benefit. Results: During a median of 43 months follow-up, 176 of 483 participants experienced the primary outcome. Selected treatment modifiers were eGFR, age, proteinuria, renin-angiotensin-aldosterone-system blockade dose, ethnicity, time from biopsy to enrollment, systolic blood pressure, sex, body mass index, and MEST-C T-score and C-score. Compared to the average ARR associated with methylprednisolone (16.1%), the predicted individual-level ARR was highly variable (-10% to 40%). Patients with predicted ARR over 10% had greater observed benefit from methylprednisolone (ARR 24%) versus those with predicted ARR 10% or less (observed ARR -5%). A policy of treating only patients with higher anticipated benefit had a longer RMST than using random treatment allocation (1,194 v 1,028 days). The C-statistic for benefit was 0.63 (95% confidence interval 0.56-0.70). The frequency of adverse events was similar across tertiles of ARR. Conclusions: We have generated a model that can ...
Τύπος εγγράφου: article in journal/newspaper
Γλώσσα: unknown
Relation: https://hdl.handle.net/1959.4/107822; https://doi.org/10.1016/j.kint.2025.12.024
DOI: 10.1016/j.kint.2025.12.024
Διαθεσιμότητα: https://hdl.handle.net/1959.4/107822
https://doi.org/10.1016/j.kint.2025.12.024
Rights: open access ; https://purl.org/coar/access_right/c_abf2 ; CC BY ; https://creativecommons.org/licenses/by/4.0/
Αριθμός Καταχώρησης: edsbas.CDCF2A0C
Βάση Δεδομένων: BASE
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://hdl.handle.net/1959.4/107822#
    Name: EDS - BASE (ns324271)
    Category: fullText
    Text: View record from BASE
Header DbId: edsbas
DbLabel: BASE
An: edsbas.CDCF2A0C
RelevancyScore: 1011
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 1010.63568115234
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment in IgA nephropathy
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Canney%2C+M%22">Canney, M</searchLink><br /><searchLink fieldCode="AR" term="%22Shan%2C+S%22">Shan, S</searchLink><br /><searchLink fieldCode="AR" term="%22Er%2C+L%22">Er, L</searchLink><br /><searchLink fieldCode="AR" term="%22Billot%2C+L%22">Billot, L</searchLink><br /><searchLink fieldCode="AR" term="%22Han%2C+J%22">Han, J</searchLink><br /><searchLink fieldCode="AR" term="%22Wong%2C+MG%22">Wong, MG</searchLink><br /><searchLink fieldCode="AR" term="%22Monaghan%2C+H%22">Monaghan, H</searchLink><br /><searchLink fieldCode="AR" term="%22Hladunewich%2C+M%22">Hladunewich, M</searchLink><br /><searchLink fieldCode="AR" term="%22Hooi%2C+LS%22">Hooi, LS</searchLink><br /><searchLink fieldCode="AR" term="%22Jha%2C+V%22">Jha, V</searchLink><br /><searchLink fieldCode="AR" term="%22Lv%2C+J%22">Lv, J</searchLink><br /><searchLink fieldCode="AR" term="%22Perkovic%2C+V%22">Perkovic, V</searchLink><br /><searchLink fieldCode="AR" term="%22Zhang%2C+H%22">Zhang, H</searchLink><br /><searchLink fieldCode="AR" term="%22Cattran%2C+DC%22">Cattran, DC</searchLink><br /><searchLink fieldCode="AR" term="%22Barbour%2C+SJ%22">Barbour, SJ</searchLink><br /><searchLink fieldCode="AR" term="%22Jha%2C+Vivekanand%22">Jha, Vivekanand</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: urn:ISSN:0085-2538 ; urn:ISSN:1523-1755 ; Kidney International, 109, 4, 738-749
– Name: Publisher
  Label: Publisher Information
  Group: PubInfo
  Data: Elsevier
– Name: DatePubCY
  Label: Publication Year
  Group: Date
  Data: 2026
– Name: Subset
  Label: Collection
  Group: HoldingsInfo
  Data: UNSW Sydney (The University of New South Wales): UNSWorks
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%2232+Biomedical+and+Clinical+Sciences%22">32 Biomedical and Clinical Sciences</searchLink><br /><searchLink fieldCode="DE" term="%223202+Clinical+Sciences%22">3202 Clinical Sciences</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+Trials+and+Supportive+Activities%22">Clinical Trials and Supportive Activities</searchLink><br /><searchLink fieldCode="DE" term="%22Kidney+Disease%22">Kidney Disease</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+Research%22">Clinical Research</searchLink><br /><searchLink fieldCode="DE" term="%22Precision+Medicine%22">Precision Medicine</searchLink><br /><searchLink fieldCode="DE" term="%226%2E1+Pharmaceuticals%22">6.1 Pharmaceuticals</searchLink><br /><searchLink fieldCode="DE" term="%22Adult%22">Adult</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Male%22">Male</searchLink><br /><searchLink fieldCode="DE" term="%22Middle+Aged%22">Middle Aged</searchLink><br /><searchLink fieldCode="DE" term="%22Adrenal+Cortex+Hormones%22">Adrenal Cortex Hormones</searchLink><br /><searchLink fieldCode="DE" term="%22Glomerular+Filtration+Rate%22">Glomerular Filtration Rate</searchLink><br /><searchLink fieldCode="DE" term="%22Glomerulonephritis%22">Glomerulonephritis</searchLink><br /><searchLink fieldCode="DE" term="%22IGA%22">IGA</searchLink><br /><searchLink fieldCode="DE" term="%22Glucocorticoids%22">Glucocorticoids</searchLink><br /><searchLink fieldCode="DE" term="%22Methylprednisolone%22">Methylprednisolone</searchLink><br /><searchLink fieldCode="DE" term="%22Proportional+Hazards+Models%22">Proportional Hazards Models</searchLink><br /><searchLink fieldCode="DE" term="%22Time+Factors%22">Time Factors</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+Outcome%22">Treatment Outcome</searchLink><br /><searchLink fieldCode="DE" term="%22Secondary+Data+Analysis%22">Secondary Data Analysis</searchLink><br /><searchLink fieldCode="DE" term="%22IgA+nephropathy%22">IgA nephropathy</searchLink><br /><searchLink fieldCode="DE" term="%22clinical+trial%22">clinical trial</searchLink><br /><searchLink fieldCode="DE" term="%22corticosteroids%22">corticosteroids</searchLink><br /><searchLink fieldCode="DE" term="%22kidney+failure%22">kidney failure</searchLink><br /><searchLink fieldCode="DE" term="%22prediction%22">prediction</searchLink><br /><searchLink fieldCode="DE" term="%22response%22">response</searchLink><br /><searchLink fieldCode="DE" term="%22TESTING+trial+steering+committee%22">TESTING trial steering committee</searchLink><br /><searchLink fieldCode="DE" term="%22anzsrc-for%3A+32+Biomedical+and+Clinical+Sciences%22">anzsrc-for: 32 Biomedical and Clinical Sciences</searchLink>
– Name: Abstract
  Label: Description
  Group: Ab
  Data: Introduction: Corticosteroids are effective for treating IgA nephropathy but have important adverse effects. In this secondary analysis of the TESTING cohort, we generated a model to predict, for an individual patient, the probability that they will respond to corticosteroids. Methods: Time to the primary outcome (40% reduction in eGFR, kidney failure or death due to kidney disease) was evaluated in a Cox proportional hazards model including all potential treatment modifiers as main effects. Selected variables were forced into a model with treatment exposure and interaction terms between treatment and each included variable. The predicted four-year absolute risk of the primary outcome was generated for every patient individually under separate scenarios of being treated with methylprednisolone or placebo. The difference between the two scenarios was the predicted individual treatment effect on absolute risk reduction (ARR). Model performance was assessed using discrimination plots, restricted mean survival time (RMST) and the C-statistic for benefit. Results: During a median of 43 months follow-up, 176 of 483 participants experienced the primary outcome. Selected treatment modifiers were eGFR, age, proteinuria, renin-angiotensin-aldosterone-system blockade dose, ethnicity, time from biopsy to enrollment, systolic blood pressure, sex, body mass index, and MEST-C T-score and C-score. Compared to the average ARR associated with methylprednisolone (16.1%), the predicted individual-level ARR was highly variable (-10% to 40%). Patients with predicted ARR over 10% had greater observed benefit from methylprednisolone (ARR 24%) versus those with predicted ARR 10% or less (observed ARR -5%). A policy of treating only patients with higher anticipated benefit had a longer RMST than using random treatment allocation (1,194 v 1,028 days). The C-statistic for benefit was 0.63 (95% confidence interval 0.56-0.70). The frequency of adverse events was similar across tertiles of ARR. Conclusions: We have generated a model that can ...
– Name: TypeDocument
  Label: Document Type
  Group: TypDoc
  Data: article in journal/newspaper
– Name: Language
  Label: Language
  Group: Lang
  Data: unknown
– Name: NoteTitleSource
  Label: Relation
  Group: SrcInfo
  Data: https://hdl.handle.net/1959.4/107822; https://doi.org/10.1016/j.kint.2025.12.024
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.1016/j.kint.2025.12.024
– Name: URL
  Label: Availability
  Group: URL
  Data: https://hdl.handle.net/1959.4/107822<br />https://doi.org/10.1016/j.kint.2025.12.024
– Name: Copyright
  Label: Rights
  Group: Cpyrght
  Data: open access ; https://purl.org/coar/access_right/c_abf2 ; CC BY ; https://creativecommons.org/licenses/by/4.0/
– Name: AN
  Label: Accession Number
  Group: ID
  Data: edsbas.CDCF2A0C
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsbas&AN=edsbas.CDCF2A0C
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.kint.2025.12.024
    Languages:
      – Text: unknown
    Subjects:
      – SubjectFull: 32 Biomedical and Clinical Sciences
        Type: general
      – SubjectFull: 3202 Clinical Sciences
        Type: general
      – SubjectFull: Clinical Trials and Supportive Activities
        Type: general
      – SubjectFull: Kidney Disease
        Type: general
      – SubjectFull: Clinical Research
        Type: general
      – SubjectFull: Precision Medicine
        Type: general
      – SubjectFull: 6.1 Pharmaceuticals
        Type: general
      – SubjectFull: Adult
        Type: general
      – SubjectFull: Female
        Type: general
      – SubjectFull: Humans
        Type: general
      – SubjectFull: Male
        Type: general
      – SubjectFull: Middle Aged
        Type: general
      – SubjectFull: Adrenal Cortex Hormones
        Type: general
      – SubjectFull: Glomerular Filtration Rate
        Type: general
      – SubjectFull: Glomerulonephritis
        Type: general
      – SubjectFull: IGA
        Type: general
      – SubjectFull: Glucocorticoids
        Type: general
      – SubjectFull: Methylprednisolone
        Type: general
      – SubjectFull: Proportional Hazards Models
        Type: general
      – SubjectFull: Time Factors
        Type: general
      – SubjectFull: Treatment Outcome
        Type: general
      – SubjectFull: Secondary Data Analysis
        Type: general
      – SubjectFull: IgA nephropathy
        Type: general
      – SubjectFull: clinical trial
        Type: general
      – SubjectFull: corticosteroids
        Type: general
      – SubjectFull: kidney failure
        Type: general
      – SubjectFull: prediction
        Type: general
      – SubjectFull: response
        Type: general
      – SubjectFull: TESTING trial steering committee
        Type: general
      – SubjectFull: anzsrc-for: 32 Biomedical and Clinical Sciences
        Type: general
    Titles:
      – TitleFull: A secondary analysis of the TESTING trial predicted individual patient response to corticosteroid treatment in IgA nephropathy
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Canney, M
      – PersonEntity:
          Name:
            NameFull: Shan, S
      – PersonEntity:
          Name:
            NameFull: Er, L
      – PersonEntity:
          Name:
            NameFull: Billot, L
      – PersonEntity:
          Name:
            NameFull: Han, J
      – PersonEntity:
          Name:
            NameFull: Wong, MG
      – PersonEntity:
          Name:
            NameFull: Monaghan, H
      – PersonEntity:
          Name:
            NameFull: Hladunewich, M
      – PersonEntity:
          Name:
            NameFull: Hooi, LS
      – PersonEntity:
          Name:
            NameFull: Jha, V
      – PersonEntity:
          Name:
            NameFull: Lv, J
      – PersonEntity:
          Name:
            NameFull: Perkovic, V
      – PersonEntity:
          Name:
            NameFull: Zhang, H
      – PersonEntity:
          Name:
            NameFull: Cattran, DC
      – PersonEntity:
          Name:
            NameFull: Barbour, SJ
      – PersonEntity:
          Name:
            NameFull: Jha, Vivekanand
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-locals
              Value: edsbas
            – Type: issn-locals
              Value: edsbas.oa
          Titles:
            – TitleFull: urn:ISSN:0085-2538 ; urn:ISSN:1523-1755 ; Kidney International, 109, 4, 738-749
              Type: main
ResultId 1